Valirx Share Price (VAL)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Valirx Plc	LSE:VAL	London	Ordinary Share	GB00BWWYSP41	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.01p	-3.51%	0.275p	8,965,744	13:45:29

Bid Price		Offer Price	High Price	Low Price	Open Price
0.25p		0.30p	0.285p	0.275p	0.285p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology		-3.55	-1.90		2.1

Related Shares
Glaxosmithkline (GSK), Astrazeneca (AZN), Bermele (BERM), Venn Life Sciences (VENN)

Valirx (VAL) Latest News

Valirx News

Date	Time	Source	Headline
23/5/2019	12:02	UKREG	ValiRx PLC Holding(s) in Company
22/5/2019	07:44	ALNCF	Alliance News Flash Headline
22/5/2019	07:00	UKREG	ValiRx PLC Subscription Agreement Update
13/5/2019	14:00	UKREG	ValiRx PLC Price Monitoring Extension
02/5/2019	15:21	ALNC	ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio
02/5/2019	07:00	UKREG	ValiRx PLC Acquisition of Intellectual Property& JV Agreement
29/4/2019	14:06	UKREG	ValiRx PLC Second Price Monitoring Extn
29/4/2019	14:01	UKREG	ValiRx PLC Price Monitoring Extension
29/4/2019	11:07	UKREG	ValiRx PLC Second Price Monitoring Extn
29/4/2019	11:01	UKREG	ValiRx PLC Price Monitoring Extension

More Valirx News

Valirx Takeover Rumours

Valirx (VAL) Share Charts

1 Year Valirx Chart

1 Month Valirx Chart

Intraday Valirx Chart

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date	Time	Title	Posts
25/5/2019	10:20	Valirx 24/07/2018 Post GM	3,736
29/4/2019	09:58	ValiRX Plc at the UK Investor Show	1
05/4/2019	20:27	Warning signs?	26
05/3/2019	11:17	Valirx 2018 for Rampers,Derampers and P&D have your say..	1,837
23/2/2019	11:44	RAINMAKER'S VALUE THREAD	8,288

Add a New Thread

Valirx (VAL) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-05-24 15:18:41	0.30	96,155	287.50	O
2019-05-24 14:58:38	0.29	600,000	1,710.00	O
2019-05-24 14:20:12	0.30	16,724	50.00	O
2019-05-24 12:53:39	0.30	700,000	2,089.50	O
2019-05-24 12:44:31	0.30	167,000	500.00	O

View all Valirx trades in real-time

Valirx (VAL) Top Chat Posts

Date	Subject
25/5/2019 09:20	Valirx Daily Update: Valirx Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 0.29p. Valirx Plc has a 4 week average price of 0.22p and a 12 week average price of 0.22p. The 1 year high share price is 3.38p while the 1 year low share price is currently 0.22p. There are currently 752,629,382 shares in issue and the average daily traded volume is 13,162,492 shares. The market capitalisation of Valirx Plc is £2,069,730.80. Read Full Thread Reply
22/5/2019 07:10	thebossman: Our share price has declined from 0.052p to 0.035p.. Tranche 2 The Company advises that admission of the Tranche 2 subscription shares is now expected to occur on or around 23 May 2019. Admission was initially expected to occur on around 21 May 2019. A further announcement will be made by the Company in due course in relation to Tranche 2. Break Fee Should the Company not receive authority from shareholders to issue sufficient shares for the purpose of the Convertible Funds, or should definitive documentation in relation to the Convertible Funds not be signed, in either case before 22 June 2019, ValiRx shall be required to pay the investor a Break Fee totalling £150,000 plus an additional amount in the event the Company's share price declines in the period to the date the Break Fee crystallises. This additional amount is to be calculated by multiplying the stock performance of the Company (expressed as a percentage) by £1,000,000. The stock performance percentage is based on any decline from a price of 0.52p, being the closing share price of the Company's shares on 19 April 2019. Read Full Thread Follow Reply
12/5/2019 20:43	spurs90: Calculation For Trading: Resistance Level (R3): 0.486 Resistance Level (R2): 0.456 Resistance Level (R1): 0.433 Pivot Point: 0.4022 Support Level (S1): 0.379 Support Level (S2): 0.349 Support Level (S3): 0.326 Questions & Answers about Valirx Projection What is the Valirx stock price / share price today? The Valirx stock price is 0.410 GBX today. Will Valirx stock price grow / rise / go up? Yes. The VAL stock price can go up from 0.410 GBX to 47.862 GBX in one year. Is it profitable to invest in Valirx stock? Yes. The long-term earning potential is +11573.76% in one year. Will VAL stock price fall / drop? No (see above). What will Valirx stock price be worth in five years (2024)? The VAL ("VAL" ) future stock price will be 8.808 GBX. Will VAL stock price crash? According to our analysis, this will not happen. Will Valirx stock price hit 1 GBX price in a year? Yes, within a year ( see above). Will Valirx stock price hit 5 GBX price in a year? Yes, within a year ( see above). Will Valirx stock price hit 10 GBX price in a year? Yes, within a year Read Full Thread Follow Reply
01/5/2019 01:42	thebossman: Nico...so what is the subscritive share price .Surely the share price must be 0.60p for valirx to get the full monies they need... An aggregate structuring fee totalling £278,000 is payable to the Investor by ValiRx in three equal instalments of £92,666.66 following each of the tranches ("Structuring Fee"), relating both to the Subscription and also the Convertible Funds (as detailed below). Tranche 1 Application is shortly to be made to the London Stock Exchange for the 71,000,000 Tranche 1 new ordinary shares, and it is expected that the shares will be admitted to trading on AIM on or around 1 May 2019 ("Tranche 1 Admission"). Following Tranche 1 Admission, the Company's enlarged issued share capital will comprise 752,629,382 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. This figure of 752,629,382 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. An aggregate structuring fee totalling £278,000 is payable to the Investor by ValiRx in three equal instalments of £92,666.66 following each of the tranches ("Structuring Fee"), relating both to the Subscription and also the Convertible Funds (as How are valirx going to pay back this loan...if our share price keeps falling...???? FD should be given the boot for this deal,unless its known that LOI will be signed very soon..??? hTTps://www.netlawman.co.uk/ia/appointment-removal-company-directors Removing directors A director holds office at the wish of the shareholders. He can be removed by a 50% vote at a meeting of the shareholders. The meeting need give no reason. A single majority shareholder automatically carries over 50% so he alone can remove a director. Retirement by rotation At each annual general meeting of the company, one-third of the total number of directors must retire from office and be subject to re-election. Shareholders can remove a director from the board simply by failing to re-elect him. Executive directors, however, are exempt from this requirement. JS..Valirx must be 100% sure that the LOI will be signed by the date you mention.. Otherwise according to your figures its going to cost the company a fortune. Read Full Thread Follow Reply
26/4/2019 18:45	johnsmith777: If Valirx's share price falls 50% and the company fails to execute documentation on the wider convertible loan package, it will owe EHGO an additional £650,000! (£150,000 break fee + £500,000 fee for the share price dropping 50%).Given how likely it seems both events will happen, EHGO must think it is on to an absolute winner with Valirx.And this is on top of the £278,000 "structuring fee" already mentioned.Using these figures, this would mean if Valirx's share price is at 0.26p on June 21 and the company fails to execute the wider convertible loan package it will owe EHGO an eye-watering £928,000. On an "investment" of £1,278,000.This is the worst kind of carcass picking profiteering we see on AIM. It would be far better just to kick these walking dead companies off the Exchange. Read Full Thread Follow Reply
10/2/2019 23:27	k9p: Is this guy for real? If he is some one should explain how things work and how to find out information and reporting to to mention how you short and sell without real exposure or even being seen Price: 0.90 RE: Forward sellingSat 11:06Can anyone tell me which firms are the MM's on VAL? (I don't have this information). I want to compile a report to go to the FCA should there be yet another placing in the next days/weeks. We all know these placings have worked in the past. People in the know, allegedly tell their mates about the confidential placing. People in the know, (the MM's?) must then collude to mark up the price knowing what's going on. People in the know, then forward sell their shares knowing they will be allocated shares cheaper from the placing. People in the know, also instruct their broker to sell shares once the sudden price increase has happened. These people then wait for the price to be ticked back down (by the MM's) and buy back cheaper. The FCA can easily: Investigate the last few placings in VAL. Find out who was involved in the confidential negotiations (and thus "inside" Find out who the MM's were for each of these recent placings. List all the "large" trades as soon as the confidential negotiations started. Ascertain which brokers placed these trades. Request these brokers to supply who their underlying client is. My guess is that IF the FCA were prepared to do a full investgation, the same MM's/brokers/clents would be involved and perhaps the FCA could find a link between those who were "inside" and those who made a quick profit. Perhaps I am way off the mark here? Perhaps its now a good time to invest in VAL and something positive is about to happen. Perhaps this is why the price ticked-up and there were lots of shares traded? Perhaps it was a "pump & dump" and just day traders forcing the price changes? No doubt we will all find out one day. However, IF a placing is about to be announced, some people who are "inside" may have broken the rules and this needs to be investigated. In this day and age and with all the "do-gooders" in the world, the above is pure speculation of course and my take on events. I am not suggesting that anyone from VAL, the MM's or brokers have broken the law. All I can do is complie my findings and send this evidence to the FCA. It will be the FCA who be judge and jury. I have close friends who have been invested in VAL for years. They invested their hard earned cash into VAL based on their own choice and have stuck with VAL believing they may recover some of their "losses" one day! I have seen how VAL's decline has affected their lives. Just when they think the VAL share price is about to start ticking up, their hopes and dreams are immediately quoshed. This has happened far too often. I welcome any comments from the geniune VAL investors who possibly feel the same way. Any advice or assistance would be greatly appreciated. I also expect the usual responses from the "trolls" who have no interest in VAL. I really do hope VAL deliver something positive soon and my friends recover some, all, or better still,more than they originally invested into VAL. Thanks ev Read Full Thread Follow Reply
11/6/2018 16:42	thebossman: Align research OPEN LETTER TO THE BOARD OF VALIRX June 10, 2018 \| Posted by admin OPEN LETTER Dear Ms Vainikka I write this letter to you in an open format as Align Research is all about transparency and, collectively with other shareholders, as ultimate owners of the company, we believe that all shareholders should be given the courtesy of weighing up the points we raise here. Whilst not wishing to be overly aggressive, should you ignore this letter and the points detailed herein, I can now confirm that we have commitments for in excess of 5% of the shareholder register to bring an EGM for your and potentially other BoD members’ removal and will, if it is necessary, not hesitate in catalysing this. I bring to your attention the following concerns we have with regards to the current stewardship of the company: Since 2016 I count that there has been six outright equity placings (with warrant overhangs to the placing brokers) aswell as the Yorkville and Bracknor facilities totalling funding of £7.75m. The share count during this period has risen from just over 43m shares to an incredible 407m – a near ten fold increase. It is safe to say that those loyal shareholders over the past two years have been veritably decimated unless they had bottomless pockets. More disconcertingly, during this period I cannot see any director participation in these fund raisings but yet you felt it appropriate in February of this year to award to the management slate options over 10% of the company. I believe the words complete misalignment are appropriate here. It is quite laughable that the prior options had strikes ranging between 43.125p and 125p – a prime example of “heads we win, tails you lose” that shareholders have suffered. As if the above is not illustrative of the fact that you are (a) disconnected from shareholders and (b) actually appearing to act at cross purposes to their interests, you have collectively as a Board taken just shy of £1m during the last 2 years. This, whilst the stock price has fallen from near 60p to less than 1p at the low point. If ever the moniker “reward for failure” was applicable, that very point surely is it. The third most damning observation re non alignment with shareholders is that your collective holding of stock is de minimis. Indeed, I cannot see that you hold any shares from the last set of Report and Accounts nor have you as a BoD participated in any of the placings over the last 2 years aside from a nominal & derisory £10k purchase apiece last spring. This is utterly incredible and to me and spells one of three things – either (a) you are collectively “potless”; which is not a good position for any management personnel to be in let alone for their shareholders, (b) you do not believe in the company’s products and development stage or (c), such is the system in place allowing you to reprice share options that you do not believe it is actually necessary to “step upto the plate” and show your alignment with your long suffering shareholders. Each of these scenarios are clearly not good for the company’s owners. The Yorkville and Bracknor de facto death spiral financings have been, in large part, the primary decimants of the stock price. As a shareholder, and given the stage of development that Valirx is now at, I want reassurance that this type of financing is no longer to be used – it is the death knell for many a company and reflects to the wider market that normal equity financing of such volume is not available. Again, not good for shareholders. Towards the tail end of last year the stock actually did rise materially on the VAL201 Clinical trial results. Given that there was a decent chunk of warrants in issue (43m) with an exercise price of 5p expiring March 2019 why did you believe it necessary to cut shareholders legs from beneath them again with a placing at 4.25p when they were beginning to be exercised? The exercise of these would have brought in over £2m – in excess of the placing sum and have been less dilutive of course. I posit that this is again illustrative of the abject disregard for existing minority shareholders by you and the BoD and that it has continued to foster the belief that management cannot be trusted not to continually throw prior placee participants under a bus. You can see from above that there is a quite damning list of non shareholder friendly activities that have taken place on your watch and the share price collapse presents, we believe, an unarguable case. The course you have taken this last few years has only served to cut both the market cap and the credibility of the company. To be clear, the purpose of this letter is to bring the current course that has been so damaging to all shareholders to a halt and with as minimum disruption to the company as possible. I do actually believe that Valirx is now on the cusp of real commercial applications of its key products but my confidence in current shareholders benefiting from this is, for obvious reasons as relayed here, extremely low. With the above in mind I would like you to show collectively as a BoD a new commitment to your shareholders through the following actions: A rebasing of your and Dr George Morris’ salary to £60,000 p.a. From a performance bonus perspective you are more than adequately incentivised now re the generous share options you recently struck yourselves with an exercise price of just 4p and near 10 years of life. The appointment of a new NED to represent shareholders interests and replacing Kevin Alexander. I am happy to liaise on an appropriate party in this role. I note CFO Mr Dessler has a loan repayable from the company of £41,030. Subject to restricted period dealing clearance I would suggest that this be converted into stock at the current price in showing his faith in the way forward. Collective directors purchasing of stock on market (subject to non restricted period dealing issues) of a minimum of £100,000 in, again, showing your faith in the way forward. A clear funding pathway disclosure over the next 18 months with a commitment to not utilise death spiral financing and a dual commitment that any such funding requirements be offered to existing shareholders by way of an open offer. I sincerely hope that you take seriously the points raised here and that you communicate with all Valirx shareholders on these issues. I repeat again, ignorance of these matters will result in the calling of an EGM for wholesale BoD replacements. Yours faithfully R Jennings If the past is anything to go by then sod all will come out of this letter.. Maybe valirx will say we are doing our best.. Read Full Thread Follow Reply
03/1/2018 20:00	margic: Good news tomorrow would be good timing from the bod. Something for the market to get stuck into. Personally I think Val 201 results would be a good catalyst and a great start. Pharma deal would be great but I suspect they will get other news filters and updates through before announcing anything should a deal go ahead. That it certainly has potential to be truly transformational for the company so would no doubt require a quick re-rate. With the share price higher of the back of Val 201 results, Val share price will be very well placed to see a huge increase on the years highs. Today, unfortunately was very predictable. Probably much the same tomorrow I would have thought. It will need a significant buying frenzy or good news to change direction this week. The gap will still be filled at some point without a shadow of a doubt. That's simply because it always does! Read Full Thread Follow Reply
03/1/2018 17:27	thebossman: ValiRx Clinical efficacy of VAL401 ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potentially other hormone- induced indications; and VAL401 (Phase II) – a reformulation of risperidone, in trials for lung cancer. Early clinical analysis of its Phase II trial with VAL401 has been released, meeting its primary endpoint by providing a statistically significant improvement in the overall survival rate. Further data will be revealed in due course. ► Strategy: ValiRx operates as a virtual business, out-sourcing most of its activities. The core strategy is to develop its therapeutic assets through the clinical pathway and seek a partner/licensing deal to complete the development programme and regulatory submissions to commercialise the products. ► Overall survival data: The newly published data on non-small cell lung cancer patients that exhausted all possible existing therapies, provide statistically significant improvement in the overall survival rate. Further analyses in quality of life and characterising the best responders will be revealed in due course. ► Valuation: This data provides an important value inflection point which was not reflected previously in the share price. The market has reacted promptly to this news, with the share price jumping from 1p at the end of November (capital increase) to 7.73p – a near eight-fold increase! ► Next steps: Safety and tolerability of VAL401 has been confirmed in late stage patients affected by non-small cell lung cancer. The study has provided also the dosing level that will be used in subsequent trials. Full data analysis is underway, and the final read-out of the study is expected in the near future. ► Investment summary: The market has failed to recognise the potential of ValiRx, fretting more about the need for more capital to advance its clinical programmes that taking a rational view of the likely success of its clinical candidates. Given the clinical progress seen to date, the company will be attracting the attention of potential commercial partners and/or institutional investors in order to achieve the true value of its assets. Read Full Thread Follow Reply
18/12/2017 22:36	margic: Nobby, thanks thats insightful and would seem an appropriate approach when you consider the levels of companies involved and that there is a procedure in place in how tenders and offers are received and/or issued/ordered. Val have confirmed discussions from what I could see. It's always nice to hope that the reason the gap held is because there's another one coming tomorrow. That's a couple of major news items in recent days and these things tend to or used to come in 3-4's . Interesting to see how Val share price now plays out. If it does go much below 7p to buy then it's advisable to wait it out for 5.5p or better if you can depending how you look at it and what your strategy here is. Mine will be different to others and different others will differ to the rest. ;) Read Full Thread Follow Reply
07/12/2017 19:14	h2owater: ValiRx shares yo-yo on fundraising and pipeline update by Phil Taylor \| Dec 1, 2017 9:07am Chairman Oliver de Giorgio-Miller says ValiRx has made big progress in the last 6 months. ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs that it hopes will net it a development partner. The U.K.-based biotech—which has just raised £1 million (around $1.3 million) in a fundraising round—expects to disclose phase 1/2 data on lead drug VAL201 in prostate cancer later this month, along with midstage data for lung cancer candidate VAL401. News of the fundraising and clinical update sparked a short-lived spike in ValiRx shares on the London AIM, although it was quickly reversed, doing little to counteract what has been a fairly steady decline in the stock over the past year. The new funds will be used for “advancing the clinical trial of VAL201 and for the preclinical progress of other programmes,” said the company in a statement, adding that it believes the share price rise is “a consequence of comments and analysis surrounding the company's developmental pipeline.” VAL201 is a peptide drug, delivered by subcutaneous injection, that is being tested in a single-agent trial in patients with locally advanced or metastatic advanced prostate carcinoma. In September, the company said it had seen signs of clinical activity, including a reduction in the prostate cancer biomarker PSA and disease stabilization, with no serious safety issues in patients treated to that date. Meanwhile, VAL401—being taken forward by ValiRx’ ValiSeek unit—is a repurposed drug, a new formulation of risperidone that has more than two decades of clinical experience as an antipsychotic treatment, and ValiRx hopes to show in the forthcoming trial that it can improve quality of life in patients with advanced lung cancer. Pharmacokinetic data reported in September showed that VAL401 behaved like current formulations of risperidone, which should allow ValiRx to reference earlier trials as prepares for additional studies and—potentially—future marketing applications. It also suggested a dose for future trials of 2mg, which is well within the usual dosing range for risperidone. ValiRx’ nonexecutive chairman Oliver de Giorgio-Miller said at the time that the company has “seen considerable progress across our therapeutic portfolio in the last six months, adding value to the company's assets and bringing us closer to the point where our clinical programmes for VAL201 and VAL401 will deliver meaningful data and will bring the company closer to finding a partner.” hTTp://www.valirx.com/events/valirx-plc-targeted-anti-cancer-therapies-val201/ Read Full Thread Follow Reply

Valirx share price data is direct from the London Stock Exchange

Your Recent History

LSE

VAL

Valirx

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190525 09:31:02